Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population‐based prospective cohort study

Evidence supporting the use of anticoagulation for the prevention of stroke and thromboembolism in patients with kidney failure on hemodialysis (HD) and atrial fibrillation (AF) is limited. We prospectively assessed the incidences of stroke and major bleeding, as well as anticoagulation strategies in patients on HD with AF.

• Publication year

  2021

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2021-08-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jth.15508PMID 34418291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D)

  2023cited by this paper
• Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease

  2020cited by this paper
• Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis.

  2020cited by this paper
• Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week.

  2019cited by this paper
• 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

  2019cited by this paper
• 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

  2019cited by this paper
• Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation

  2019cited by this paper
• Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

  2019cited by this paper
• Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.

  2019cited by this paper
• Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States

  2018cited by this paper
• Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  2018cited by this paper
• Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis

  2017cited by this paper
• Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis.

  2017cited by this paper
• Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease

  2017cited by this paper
• Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)

  2017cited by this paper
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

  2016cited by this paper
• The Risk of Major Hemorrhage with CKD.

  2016cited by this paper
• Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.

  2016cited by this paper
• Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort

  2016cited by this paper
• Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.

  2015cited by this paper
• Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis

  2015cited by this paper
• Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

  2015cited by this paper
• Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.

  2015cited by this paper
• Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis.

  2014cited by this paper
• Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis

  2014cited by this paper
• Risk of stroke in long-term dialysis patients compared with the general population.

  2014cited by this paper
• Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists.

  2012cited by this paper
• Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial.

  2012cited by this paper
• Stroke and bleeding in atrial fibrillation with chronic kidney disease.

  2012cited by this paper
• Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report

  2012cited by this paper
• Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?

  2012cited by this paper
• Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study

  2011cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.

  2010cited by this paper
• Editorial comment.

  2010cited by this paper
• Atrial fibrillation in incident dialysis patients.

  2009cited by this paper
• Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.

  2009cited by this paper
• Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

  2009cited by this paper
• Dialysis Accelerates Medial Vascular Calcification in Part by Triggering Smooth Muscle Cell Apoptosis

  2008cited by this paper
• Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates.

  2007cited by this paper
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

  2004cited by this paper
• Elevated risk of stroke among patients with end-stage renal disease.

  2003cited by this paper
• Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

  2003cited by this paper
• Incidence of Stroke among Chronic Hemodialysis Patients with Nonrheumatic Atrial Fibrillation

  2001cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993cited by this paper

• Prediction of bleeding and thromboembolic complications in patients on chronic hemodialysis with the total thrombus-formation analysis system.

  2026cites this paper
• Predictors for future bleeding in bleeding disorder of unknown cause.

  2025cites this paper
• Venous Thromboembolism and Vascular Access Thrombosis in Patients on Hemodialysis: Incidence, Risk Factors, and Use of Antithrombotic Agents

  2025cites this paper
• Hemophilia is associated with accelerated biological aging

  2025cites this paper
• Oral anticoagulant therapy for patients with atrial fibrillation on long‐term dialysis: A network meta‐analysis of 137,574 patients

  2025influential citation
• Association of hemoglobin glycation index with all-cause mortality in critically ill patients with atrial fibrillation: a retrospective analysis from MIMIC-IV

  2025cites this paper
• Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events.

  2025cites this paper
• Stroke Prevention in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review

  2025cites this paper
• Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation on Long‐Term Dialysis

  2025cites this paper
• Clonal Hematopoiesis and Cardiovascular Events in Patients with End-Stage Kidney Disease on Hemodialysis: Results from the VIVALDI Study.

  2025cites this paper
• Transfer RNAs are Linked to Ischemic Stroke and Major Bleeding in Patients with End-Stage Kidney Disease

  2024cites this paper
• Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists

  2024cites this paper
• Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path

  2024cites this paper
• From arteries to veins: the expanding role of lipid-lowering drugs in preventing thrombosis.

  2024cites this paper
• Telomere length is associated with increased risk of cardiovascular events in patients with end-stage kidney disease on hemodialysis.

  2024cites this paper
• A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis

  2024cites this paper
• Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study

  2024cites this paper
• The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo

  2024cites this paper
• Outcomes of venous thromboembolism care: future directions.

  2023cites this paper
• Growth differentiation factor-15 (GDF-15) predicts major bleeding, major adverse cardiac events, and mortality in patients with end-stage kidney disease on hemodialysis: findings from the VIVALDI study.

  2022cites this paper
• Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence

  2022cites this paper
• Management of anticoagulation in hemodialysis: Results from a survey of current clinical practice in the Italian anticoagulation clinics.

  2022cites this paper
• Patient specific approach to analysis of shear-induced platelet activation in haemodialysis arteriovenous fistula

  2022cites this paper
• A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease

  2022cites this paper
• Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study

  2022cites this paper
• Bleeding Risk Assessment in End-Stage Kidney Disease: Validation of Existing Risk Scores and Evaluation of a Machine Learning-Based Approach

  2021cites this paper
• Schlaganfallprophylaxe bei Hämodialyse – eine Gratwanderung

  2021cites this paper